pembrolizumab

You have access
Effects of Pembrolizumab in Recurrent/Metastatic Squamous Cell Head and Neck Carcinoma: A Multicenter Retrospective Study
TAKURO OKADA, CHIHIRO FUSHIMI, TAKASHI MATSUKI, KUNIHIKO TOKASHIKI, HIDEAKI TAKAHASHI, ISAKU OKAMOTO, HIROKI SATO, TAKAHITO KONDO, KENJI HANYU, TAKUMA KISHIDA, TATSUYA ITO, GAI YAMASHITA, TATSUO MASUBUCHI, YUICHIRO TADA, KOKI MIURA, GO OMURA, TAKU YAMASHITA, NOBUHIKO ORIDATE and KIYOAKI TSUKAHARA

Anticancer Research June 2023, 43 (6) 2717-2724; DOI: https://doi.org/10.21873/anticanres.16438
You have access
Complete Response to Immune Checkpoint Inhibition in a Platinum Resistant Primary Ovarian Cancer Patient With Lynch Syndrome: A Case Report and Review of the Literature
LUKAS CHINCZEWSKI, FELIX WILHELM FELDHAUS, WOLFGANG SCHMITT, IOANA BRAICU, EVA ROSER and JALID SEHOULI

Anticancer Research April 2023, 43 (4) 1655-1662; DOI: https://doi.org/10.21873/anticanres.16317
Open Access
Atezolizumab Retains Cellular Binding to Programmed Death Ligand 1 Following Aerosolization via Mesh Nebulizer
GINTARAS ZALESKIS, MARTYNAS TALAIKIS, DAINIUS CHARACIEJUS, VINCAS URBONAS, PAULIUS BOSAS, ADAS DARINSKAS, LAVIJA ZIBUTYTE, LUKAS SIMKUS, ZILVINAS SURVILA, JURGITA JURSENAITE and MARGARITA ZVIRBLE

Anticancer Research March 2023, 43 (3) 1065-1072; DOI: https://doi.org/10.21873/anticanres.16251
Open Access
Real-world Data of Palliative First-line Checkpoint Inhibitor Therapy for Head and Neck Cancer
SANDRO M. WAGNER, TERESA MAGNES, THOMAS MELCHARDT, DOMINIK KIEM, LUKAS WEISS, DANIEL NEUREITER, CHRISTINA WAGNER, MARIE-BERNADETTE ARETIN, STEFAN NEMEC, GABRIELE GAMERITH, GEORG PALL, RICHARD GREIL and THORSTEN FUEREDER

Anticancer Research March 2023, 43 (3) 1273-1282; DOI: https://doi.org/10.21873/anticanres.16274
You have access
First-line Chemotherapy Response Is Associated With Clinical Outcome During Immune Checkpoint Inhibitor Treatment in Advanced Urothelial Carcinoma: A Real World Retrospective Study
JIAN-RI LI, SHIAN-SHIANG WANG, KEVIN LU, CHAUN-SHU CHEN, CHEN-LI CHENG, SHENG-CHUN HUNG, KUN-YUAN CHIU, CHIANN YI HSU and CHENG-KUANG YANG

Anticancer Research March 2023, 43 (3) 1331-1339; DOI: https://doi.org/10.21873/anticanres.16281
You have access
Association Between Body Mass Index and Outcomes in Patients With Urothelial Carcinoma Treated With Pembrolizumab
IKKO TOMISAKI, MIRII HARADA, SHIGERU SAKANO, MICHIKAZU TERADO, RYOICHI HAMASUNA, SHUJI HARADA, HIROOMI MATSUMOTO, SOICHIRO AKASAKA, YUJIRO NAGATA, AKINORI MINATO, KEN-ICHI HARADA and NAOHIRO FUJIMOTO

Anticancer Research January 2023, 43 (1) 269-274; DOI: https://doi.org/10.21873/anticanres.16159
Open Access
Real-world Therapeutic Outcomes of the Pembrolizumab Regimen as First-line Therapy for Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck: A Single-center Retrospective Cohort Study in Japan
DAISUKE SANO, MOTOHIKO TOKUHISA, HIDEAKI TAKAHASHI, TAKASHI HATANO, GOSHI NISHIMURA, YASUSHI ICHIKAWA and NOBUHIKO ORIDATE

Anticancer Research September 2022, 42 (9) 4477-4484; DOI: https://doi.org/10.21873/anticanres.15948
You have access
Real-world Experience With Pembrolizumab for Advanced-stage Head and Neck Cancer Patients: A Retrospective, Multicenter Study
TAKAFUMI NAKANO, RYUJI YASUMATSU, KAZUKI HASHIMOTO, RYOSUKE KUGA, TAKAHIRO HONGO, HIDETAKA YAMAMOTO, MIOKO MATSUO, TAKAHIRO WAKASAKI, RINA JIROMARU, TOMOMI MANAKO, SATOSHI TOH, MUNEYUKI MASUDA, MORIYASU YAMAUCHI, YUICHIRO KURATOMI, MASAHIKO TAURA, TORANOSHIN TAKEUCHI and TAKASHI NAKAGAWA

Anticancer Research July 2022, 42 (7) 3653-3664; DOI: https://doi.org/10.21873/anticanres.15854
You have access
Early Serum and Hematological Responses to Pembrolizumab Therapy as Predictors of Survival in Metastatic Urothelial Cancer
MOTOHIRO FUJIWARA, RYO FUJIWARA, TETSUYA URASAKI, TOMOHIKO OGUCHI, YOSHINOBU KOMAI, NOBORU NUMAO, SHINYA YAMAMOTO, JUNJI YONESE and TAKESHI YUASA

Anticancer Research April 2022, 42 (4) 2045-2051; DOI: https://doi.org/10.21873/anticanres.15685
You have access
Impact of the Use of Proton Pump Inhibitors on Pembrolizumab Effectiveness for Advanced Urothelial Carcinoma
IKKO TOMISAKI, MIRII HARADA, AKINORI MINATO, YUJIRO NAGATA, RIEKO KIMURO, KATSUYOSHI HIGASHIJIMA, KENICHI HARADA and NAOHIRO FUJIMOTO

Anticancer Research March 2022, 42 (3) 1629-1634; DOI: https://doi.org/10.21873/anticanres.15638

Main menu

User menu

Search

pembrolizumab

Pages